The impact of co-morbidity on life expectancy among men with localized prostate cancer.
OBJECTIVE
We evaluated 3 indexes used to assess patient co-morbidities to determine whether they could predict mortality among men with clinically localized prostate cancer.


METHODS
We measured the impact of co-morbidity classifications on all cause mortality using a parametric proportional hazards model based on a retrospective cohort analysis.


RESULTS
Each index tested is a highly significant predictor of mortality for patients dying of nonprostate cancer related causes after adjusting for age and Gleason score.


CONCLUSIONS
Each co-morbidity index provides significant, independent predictive information concerning patient mortality beyond that provided by age, Gleason score and clinical stage alone.
Albertsen
P C
PC
Department of Surgery, University of Connecticut Health Center, Farmington, USA.
Fryback
D G
DG
Storer
B E
BE
Kolon
T F
TF
Fine
J
J
D000368:Aged; D016009:Chi-Square Distribution; D015331:Cohort Studies; D015897:Comorbidity; D006801:Humans; D008017:Life Expectancy; D008297:Male; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000401:mortality*; D012189:Retrospective Studies